DINGDANG HEALTH TECHNOLOGY GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.06 HKD | +0.95% |
|
+4.95% | -46.73% |
| Apr. 01 | Dingdang Health Technology Slashes Losses in 2023 | MT |
| Mar. 28 | Dingdang Health Technology Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 13,791 | 2,426 | 1,322 | - | - |
| Enterprise Value (EV) 1 | 12,743 | 2,426 | 1,322 | 1,322 | 1,322 |
| P/E ratio | -3.05 x | -10.6 x | -14.1 x | -98.6 x | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 3.19 x | 0.5 x | 0.24 x | 0.22 x | 0.19 x |
| EV / Revenue | 3.19 x | 0.5 x | 0.24 x | 0.22 x | 0.19 x |
| EV / EBITDA | -71.7 x | -17.3 x | 28.7 x | 9.51 x | - |
| EV / FCF | -38.1 x | - | -11.7 x | 60.1 x | 13.5 x |
| FCF Yield | -2.62% | - | -8.55% | 1.66% | 7.41% |
| Price to Book | 6.31 x | 1.19 x | 0.68 x | 0.68 x | - |
| Nbr of stocks (in thousands) | 1,341,473 | 1,341,473 | 1,341,473 | - | - |
| Reference price 2 | 10.28 | 1.809 | 0.9858 | 0.9858 | 0.9858 |
| Announcement Date | 3/28/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 4,329 | 4,857 | 5,412 | 6,040 | 6,850 |
| EBITDA 1 | - | -192.4 | -140.6 | 46 | 139 | - |
| EBIT 1 | - | -327.7 | -280.6 | -133 | -49.5 | 7 |
| Operating Margin | - | -7.57% | -5.78% | -2.46% | -0.82% | 0.1% |
| Earnings before Tax (EBT) 1 | - | -2,832 | -221.2 | -123 | -39.5 | 37 |
| Net income 1 | -1,578 | -2,833 | -225.8 | -120.5 | -37 | 31 |
| Net margin | - | -65.45% | -4.65% | -2.23% | -0.61% | 0.45% |
| EPS 2 | -3.310 | -3.370 | -0.1700 | -0.0700 | -0.0100 | - |
| Free Cash Flow 1 | - | -362 | - | -113 | 22 | 98 |
| FCF margin | - | -8.36% | - | -2.09% | 0.36% | 1.43% |
| FCF Conversion (EBITDA) | - | - | - | - | 15.83% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 316.13% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/31/22 | 3/28/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 1,048 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -362 | - | -113 | 22 | 98 |
| ROE (net income / shareholders' equity) | - | - | -10.7% | -6% | -1.85% | 1.5% |
| ROA (Net income/ Total Assets) | - | - | -7.1% | -3% | -0.3% | - |
| Assets 1 | - | - | 3,181 | 4,017 | 12,333 | - |
| Book Value Per Share 2 | - | 1.630 | 1.520 | 1.450 | 1.440 | - |
| Cash Flow per Share 2 | - | - | -0 | 0.0100 | 0.0800 | - |
| Capex 1 | - | 17.7 | 13.9 | 46.5 | 47 | 15 |
| Capex / Sales | - | 0.41% | 0.29% | 0.86% | 0.78% | 0.22% |
| Announcement Date | 8/31/22 | 3/28/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.9858
CNY
Average target price
1.45
CNY
Spread / Average Target
+47.09%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -46.73% | 180M | |
| -54.62% | 10.13B | |
| -44.50% | 8.54B | |
| -19.34% | 6.49B | |
| -3.00% | 6.29B | |
| +92.00% | 5.25B | |
| -2.48% | 4.61B | |
| +6.16% | 4.55B | |
| -31.43% | 3.72B | |
| +6.00% | 3.1B |
- Stock Market
- Equities
- 9886 Stock
- Financials Dingdang Health Technology Group Ltd.
